Rakuten Medical, Inc.

Duarte, California

OncologyPhase III

What changed

Phase III trial registered: A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

9mo agoTrial registeredOct 15, 2025Source filing (opens the source filing in a new tab)

Momentum

59no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
F30 · $58k · non-dilutive
Jun 12, 2025
UNIVERSITY OF ILLINOIS AT CHICAGO · PI CHEN, ELISE · NIA · award ends Jun 11, 2028 · Cultivating Regular Physical Activity: Associations among Purpose in Life, Physical Activity, and Cognitive Function in Alzheimer's Disease and Related Dementias
NIH RePORTER · NIH RePORTER 11163684 (opens the source filing in a new tab)
Grant
R01 · $440k · non-dilutive
Mar 1, 2025
UT SOUTHWESTERN MEDICAL CENTER · PI CHEN, ELIZABETH H · NIAMS · award ends Feb 28, 2030 · Molecular Mechanisms of Myoblast Fusion
NIH RePORTER · NIH RePORTER 11027163 (opens the source filing in a new tab)
Trial
PHASE3 registered
Dec 24, 2024
Recurrent Head and Neck Squamous Cell Carcinoma · RECRUITING · sponsor: Rakuten Medical, Inc. · A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
ClinicalTrials.gov · NCT06699212 (opens the source filing in a new tab)
Grant
R35 · $451k · non-dilutive
May 4, 2020
UT SOUTHWESTERN MEDICAL CENTER · PI CHEN, ELIZABETH H · NIGMS · award ends Apr 30, 2030 · Decoding the mechanisms of cell-cell fusion - Renewal - 1
NIH RePORTER · NIH RePORTER 11091231 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator CHEN, ELIZABETH H is named on this company's filings"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
new_entity links the trial record at 0.25{"reasons":["same therapeutic area"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase III trial registered: A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
9mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
9mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH F30 · $0.1M · Cultivating Regular Physical Activity: Associations among Purpose in Life, Physical Activity, and Cognitive Function in Alzheimer's Disease and Related Dementias
Jun 2025New grantSource (opens the source filing in a new tab)
NIH R35 · $0.5M · Decoding the mechanisms of cell-cell fusion - Renewal - 1
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.4M · Molecular Mechanisms of Myoblast Fusion
Feb 2025New grantSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

F30 · $58k · non-dilutive

R01 · $440k · non-dilutive

PHASE3 registered

R35 · $451k · non-dilutive